GLP-1s Explained: Semaglutide, Tirzepatide, and Beyond

Semaglutide, tirzepatide, and retatrutide are often talked about as three versions of the same drug, just newer and stronger each time. That's not quite right. Each one activates a different number of hormone receptors, and each additional receptor changes what the drug actually does in the body, not just how well it works. Understanding that difference is the fastest way to make sense of where GLP-1 medications are headed next.

Semaglutide: The GLP-1 Foundation

Semaglutide is a synthetic version of GLP-1, a hormone your gut already releases after you eat. It was first approved by the FDA in 2017 as Ozempic for type 2 diabetes, then approved at a higher dose in 2021 as Wegovy for chronic weight management. In December 2025, the FDA approved an oral tablet version of Wegovy, making it the first GLP-1 pill approved specifically for weight loss rather than diabetes.

Semaglutide activates a single receptor, GLP-1, but that one receptor touches several systems at once. In the brain, it turns up the signals that say you're full and quiets the signals that drive hunger, while also dulling the reward response that makes certain foods hard to resist. In the stomach, it slows down how quickly food empties into the small intestine, so meals keep you full longer. In the pancreas, it boosts insulin release only when blood sugar is already elevated, and dials down glucagon, the hormone that tells your liver to release stored sugar. A modified backbone lets it bind tightly to albumin in the blood, which is what stretches its effect out to a full week between doses.

The results are backed by some of the largest obesity trials ever run. In the STEP-1 trial, adults without diabetes lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% on placebo. The SELECT trial, which enrolled over 17,000 people with cardiovascular disease and obesity but not diabetes, found semaglutide cut the risk of heart attack, stroke, or cardiovascular death by 20%, evidence that the benefit isn't just about the number on the scale. A separate trial, FLOW, found a 24% reduction in serious kidney complications in people with type 2 diabetes and chronic kidney disease. Semaglutide has, by a wide margin, the deepest base of published human data of any drug in this category.

Tirzepatide: Adding a Second Signal

Tirzepatide activates two receptors at once: GLP-1, the same one semaglutide targets, and GIP, a second gut hormone released after eating. It's FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity, both the same molecule under different labels.

For years, researchers assumed blocking GIP, not activating it, would help with weight loss. The clinical data went the other way. Turning GIP receptors on, alongside GLP-1, improves how responsive the pancreas is to rising blood sugar and appears to help fat and muscle cells use nutrients more efficiently, rather than leaving extra sugar and fat circulating in the blood. Tirzepatide is also engineered to lean on GLP-1 in a specific way, favoring the signaling pathway that drives insulin release over the one that pulls the receptor out of action, which appears to be part of why it's tolerated at least as well as semaglutide despite doing more.

The head-to-head data is the most direct evidence of what the second receptor adds. In SURMOUNT-1, the highest tirzepatide dose produced up to 22.5% average weight loss over 72 weeks. In SURMOUNT-5, a trial that put tirzepatide against semaglutide directly in the same adults over the same 72 weeks, tirzepatide produced 20.2% average weight loss compared to 13.7% for semaglutide, and fewer people stopped treatment due to gastrointestinal side effects on tirzepatide, not more. In SURPASS-2, tirzepatide outperformed semaglutide for blood sugar control in people with type 2 diabetes at every dose tested. Body composition scans from SURMOUNT-1 found the weight lost was roughly 75% fat and 25% lean mass, in line with placebo, though on a large total loss that still means real lean mass is part of the number, which is exactly why protein intake and resistance training stay part of any serious protocol.

The research beyond weight loss has moved quickly. In SYNERGY-NASH, tirzepatide resolved fatty liver disease without worsening scarring in up to 62% of participants, versus 10% on placebo. In SURMOUNT-OSA, it reduced sleep apnea severity by up to 62.8% and resolved the condition entirely in roughly half of participants. In SURPASS-CVOT, it matched an older injectable diabetes drug for cardiovascular safety with a trend toward doing better, though that trend didn't reach statistical significance. A smaller, more recent study also found that reducing excess body fat this way raised testosterone levels in men with obesity-related low testosterone, which tracks with the basic biology: excess fat tissue converts testosterone into estrogen, so losing the fat lets the body's own hormone production recover rather than requiring outside replacement. That particular finding is still early and needs to be confirmed in larger trials before it changes how anyone is treated.

Retatrutide: A Third Signal, Still in Trials

Retatrutide goes one step further, activating GLP-1, GIP, and a third receptor, glucagon. Glucagon is usually thought of only as the hormone that raises blood sugar, but at the receptor level it also increases how much energy your body burns at rest. Pairing that with the appetite-suppressing effects of GLP-1 and GIP is the theory behind why retatrutide has produced the largest weight loss numbers of any drug in this class so far.

The Phase 2 trial, published in the New England Journal of Medicine, first showed that signal in humans. Lilly's Phase 3 TRIUMPH program has since gone further: in TRIUMPH-1, participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks, with those who stayed on treatment to 104 weeks averaging 30.3%, a number in the range typically associated with bariatric surgery. TRIUMPH-2 and TRIUMPH-3, run in people with type 2 diabetes and with established cardiovascular disease respectively, showed smaller but still substantial results, consistent with what's been seen for other drugs in this class when tested in sicker populations.

Here's the part worth being direct about: retatrutide is not available to patients, and there's no confirmed date for when it will be. It is not FDA-approved for any use. Lilly has stated it plans to submit its formal FDA application, a Biologics License Application, in the first quarter of 2027. Submitting an application isn't the same as getting one approved. A standard FDA review typically runs another 10 to 12 months after submission, which puts a realistic earliest public availability somewhere in 2028, and that assumes the application goes smoothly, which isn't guaranteed for any drug. Anyone telling you a firm release date sooner than that is guessing.

What They Have in Common: Side Effects and Safety

All three drugs share the same basic side-effect profile, because they all work partly by slowing digestion. Nausea, constipation, and occasional vomiting are the most common complaints, especially in the first few weeks and right after a dose increase, which is why every approved protocol starts low and titrates up gradually rather than jumping to a full dose on day one. Rare but more serious risks include pancreatitis and gallbladder problems, and all three carry a labeled warning about thyroid C-cell tumors based on rodent studies, which is why a personal or family history of certain thyroid cancers or the related MEN2 syndrome rules someone out as a candidate. It's worth noting that a large 2025 real-world study of people with type 2 diabetes found no increased thyroid tumor risk in actual patients taking GLP-1 drugs compared with other diabetes medications, which is reassuring, though it doesn't erase the labeled precaution for people in the higher-risk groups it was written for.

The other shared reality is that none of this works in isolation. These drugs make a calorie deficit easier to sustain, not automatic, and the lean mass considerations that come up with tirzepatide apply in some degree to all of them. Protein intake and resistance training aren't optional extras here; they're part of what determines whether the weight lost is mostly fat or includes more muscle than necessary.

How to Think About Where Each One Fits

More receptors isn't automatically the right answer for every person. Semaglutide has the longest track record, the most published outcomes data of any drug on this list, and a well-understood safety profile, which matters if you value predictability over the largest possible number. Tirzepatide takes on more at the receptor level and the data shows it: more weight loss, at least as good tolerability, and a fast-growing list of benefits beyond the scale. Retatrutide may eventually add a third piece to that picture, but until it clears FDA review, it's a research result, not a treatment option.

That's exactly why Motion's Weight & Metabolism protocols are built on the two options that are actually approved and available today, matched to your labs, history, and goals by a licensed clinician, rather than a one-size-fits-all default to whichever drug is newest.